Will 2018 be the year of biotech M&A?

We are just a month into 2018 and the biotech sector is already seeing a significant pickup in merger and acquisition (M&A) deals.   In just the past 30 days, there has been already $27.5 billion USD in deals within the biotech sector.  Highlights include Sanofi’s acquisition of Bioverativ, Celgene’s buyout of Juno Therapeutics, and Takeda Pharmaceutical buying TiGenix.

M&A becomes normal for driving innovation and growth in Life Science. At Tenthpin Management Consultants, we recognize the complexities of a technology-driven industry such as Biotechnology (Biotech), with the inherent demands of innovation through research and development. Through creative approaches, our team can assist in achieving enhanced performance in a rapidly changing marketplace. A systematic approach to achieving results underpins our clients’ successes, supported by a deep understanding of the regulatory framework. With its experts in combining industry and M&A knowledge with the latest technology drivers, Tenthpin makes integrations or divestments more effective and efficient. Contact our industry experts at Tenthpin Management Consultants if you would like to learn more.

Stay up to date with the latest #LifeSciences #Pharma #MedDevices #AnimalHealth news by following us on Twitter @TenthpinMC Instagram #LifeAtTenthpin Facebook Tenthpin Management Consultants  and our Tenthpin Management Consultants LinkedIn corporate page.